PYC Therapeutics Limited
1.81
AUD
+0.01
(+0.56%)
ISIN
AU000000PYC7
Return %
Stock
S&P 500
1Y
48.87
14.20
3Y
225.13
81.12
5Y
30.05
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Rohan Hockings
- Full Time Employees
- 37
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Harry Perkins Institute of Medical Research Nedlands WA Australia 6009
- IPO Date
- Mar 3, 2005
- Website
- pyctx.com
- Similar Companies
- Business
- PYC Therapeutics Limited is a biotechnology company specializing in the development of next-generation genetic medicines to treat rare, serious genetic diseases. Its core products and services include the research, development, and commercialization of peptide-conjugated antisense oligonucleotides (PPCs), which are designed to target genetic mutations at the RNA level. The company focuses on delivering therapies primarily in the neuromuscular, neurological, and systemic disease areas. Key product candidates address conditions such as Duchenne muscular dystrophy (DMD) and other genetic disorders, leveraging proprietary conjugate technology to enhance tissue targeting and drug delivery. PYC Therapeutics operates mainly in Australia and has a global development footprint with collaborations and partnerships to advance its pipeline. Recent major company changes include strategic partnerships and clinical advancement milestones, with PYC Therapeutics expanding its pipeline through collaborations and progressing clinical trials of its lead candidates. The company has raised significant funding rounds to accelerate development and has made strides in extending its technology platform to new therapeutic areas within genetic medicine. These developments underscore the company’s focus on enhancing its product portfolio and operational capabilities to solidify its position in the rare disease market. Founded in 2011 and headquartered in Melbourne, Australia, PYC Therapeutics operates within the biotechnology and pharmaceutical industry segments. Its target markets comprise patients with rare genetic conditions, healthcare providers in specialized care, and global pharmaceutical partners. As a growth-stage biotech, PYC maintains a strong R&D focus with an emphasis on innovative molecular therapeutics. It remains an independent company listed on the Australian Securities Exchange under the ticker PYC.AX. This description captures PYC Therapeutics’ comprehensive product offerings, recent strategic developments, and geographic and operational context in alignment with financial data provider standards.